MedPage Today on MSN2d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...
News-Medical.Net on MSN2d
Researchers develop new compound to treat alopecia areataA research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...
The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the ...
In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...
The researchers tested their new itaconate-based prodrugs in mice and found that at least two of them were highly effective. The treatment was well-absorbed, reduced inflammation, and stimulated hair ...
Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...
Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...
Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback